$2.92
$7.70
52-Week Range
At a Glance
AI-generated6-K
Regentis Biomaterials Ltd. announced the expansion of its European clinical site network into Italy, Germany, Serbia, Slovenia, and Romania to support its commercial launch of GelrinC®, which has CE Mark approval for knee cartilage repair, and ongoing clinical programs including a Phase III FDA study over 50% enrolled. This strengthens engagement with leading orthopedic surgeons and centers of excellence ahead of the 2026 European launch.$12M
Market Cap
—
Revenue
—
Net Income
Fundamentals
How The Business Makes Money
Regentis Biomaterials Ltd., a regenerative medicine company, develops tissue repair solutions that restore the health and enhance quality of life of patients. Its lead product candidate is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries and articular knee cartilage. The company focuses on developing orthopedic treatments using its Gelrin platform that is based on degradable hydrogel implants to regenerate damaged or diseased tissue. Regentis Biomaterials Ltd. was incorporated in 2004 and is based in Herzliya, Israel.
Industry Medical - Instruments & Supplies
Activity
What Changed Recently
Company Profile
CIK0001912966
ISINIL0012190968
CUSIP001219096
Phone972 9 960 1917
Address60 Medinat Hayehudim Street, Herzliya, 4676652, IL
SEC EDGAR